Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

Iterion Therapeutics' CEO, Rahul Aras, discusses the company's capital-efficient drug development approach, particularly for its lead candidate, Tegavivint, targeting the Wnt-Beta-Catenin pathway in oncology. Rahul shares Iterion's strategic focus on hepatocellular carcinoma (HCC) due to its unique biology, clinical white space, and potential for accelerated approval. He highlights the company's ability to progress from concept to human proof of concept in HCC and desmoid tumors with less than $50 million in equity capital, supplemented by grant funding. Rahul also addresses the challenges and benefits of operating outside major biotech hubs like Boston, emphasizing the importance of strong academic collaborations and community support in Houston.